From CLL to Multiple Myeloma ‐ Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration

Arnaud Petit Andr e Baruchel Jacqueline Clavel Benôıt Brethon Yves Bertrand Patrick Lutz Fabienne Nacka St ephane Ducassou Unit of Paediatric Haematology and Oncology, Bordeaux University Hospital, Bordeaux-Cedex, Unit of Paediatric Haematology and Oncology, Armand Trousseau Hospital, Unit of Paediatric Haematology and Immunology, Robert Debr e Hospital, Paris, Institut National de la Sant e et de la recherche M edicale (INSERM), Unit754, Registry of Malignant Hemopathies in childhood, Villejuif, Institute of Paediatric Haematology and Oncology, 1, place du Professeur Joseph Renault, Lyon, Unit of Paediatric Haematology and Oncology, Hautepierre Hospital, Strasbourg, and Clinical Investigation Centre in Paediatrics CIC 1401, Bordeaux University Hospital, Bordeaux-Cedex, France E-mail: stephane.ducassou@chu-bordeaux.fr

[1]  M. Beksac,et al.  European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma , 2014, Haematologica.

[2]  R. Wäsch,et al.  Preclinical models of multiple myeloma: a critical appraisal , 2013, Expert opinion on biological therapy.

[3]  R. Wäsch,et al.  Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138‐downregulation and inhibition of migration through actin depolymerization , 2013, British journal of haematology.

[4]  L. Staudt,et al.  Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.

[5]  鄒欣霓.  探討角質細胞spleen tyrosine kinase在IL-17引發CCL20表現所扮演的角色 , 2012 .

[6]  C. Burns,et al.  The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells , 2011, Leukemia.

[7]  Ronald Levy,et al.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.

[8]  S. Stilgenbauer,et al.  Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. , 2009, Blood.

[9]  Jens Timmer,et al.  Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. , 2009, Cancer research.

[10]  J. Miguel,et al.  Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals , 2007, Leukemia.

[11]  K. Moelling,et al.  Phosphorylation and regulation of Raf by Akt (protein kinase B). , 1999, Science.